


Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in My Watchlist
Most Trending
+4.16%
-0.88%
-6.48%
-3.96%
+11.82%
INSM
Insmed
$159.27
Strengths

Upgraded on attractively valued

Earnings are forecast to grow

Outperform the market
INSM Price Performance
$198.46 (-19.75%)
$167.91 (-5.15%)
$131.88 (+20.77%)
$76.58 (+107.98%)
INSM has Fair risk level based on volatility, sector strength, volume, investor confidence and outlook.
Click here to check what is your level of risk
Risks Indicators

Beta greater than 1.0

INSM overall standing based on key factors, offering insights into analysts perspectives and market expectations.
Hover over the category for more information
Earnings
Earnings

Above analyst estimates
Rating
Rating

Upgraded on attractively valued
Momentum
Momentum

Has been gaining momentum
Activity
Activity
Future
Future

Earnings are forecast to grow

Outperform the market
![]()
INSM Analysts opinion is negative and it remained unchanged from the past 3 months
Analysts perspectives on the stock desirability, trend direction and growth potential
INSM Street Sentiment is extremely bullish and have positive views on the near-term outlook
Average key support and resistance price levels
SNY
47.47
-0.88%
XOMA
28.79
-1.94%
REGN
741.92
-1.62%
MRK
110.95
-0.06%
MLTX
16.35
-6.09%
TIMB
TIM S.A.
21.65
+2.58%
INSM
Insmed
159.27
-2.56%
SGC
Superior Group of
10.20
-0.20%
NAII
Natural Alternatives Inte
4.64
-2.32%
WAFD
Washington Federal
33.73
+2.09%
What is INSM current stock price?
What are INSM stock strengths?
What is INSM Risk Level?
What is INSM market cap and volume?
What is INSM current Stock IQ?
Should I buy INSM stock right now?
Is INSM a Strong Buy right now?
What does a 'Strong Buy' rating mean for INSM?
What does a 'Strong Sell' rating mean for INSM?
What factors influence INSM's Stock IQ?
Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts
Stay ahead of the market
Market trends
Investment tips
Market analysis service
Future potential
Informed investment decisions
Investment analysis
IInvestment strategies
In-depth stock analysis
Performance analysis
Stock market insights
Financial trends analysis
Most Trending
+4.16%
-0.88%
-6.48%
-3.96%
+11.82%
INSM
Insmed
Current Price
$159.27
INSM Stock IQ
Stock Insights
Strengths

Upgraded on attractively valued

Earnings are forecast to grow

Outperform the market
Linked to INSM
SNY
47.47
-0.88%
XOMA
28.79
-1.94%
REGN
741.92
-1.62%
MRK
110.95
-0.06%
MLTX
16.35
-6.09%
Recently Viewed
TIMB
TIM S.A.
21.65
+2.58%
INSM
Insmed
159.27
-2.56%
SGC
Superior Group of
10.20
-0.20%
NAII
Natural Alternatives Inte
4.64
-2.32%
WAFD
Washington Federal
33.73
+2.09%

INSM Price Performance
$198.46 (-19.75%)
$167.91 (-5.15%)
$131.88 (+20.77%)
$76.58 (+107.98%)
INSM Analysts Opinion
INSM Overall standing by considering key factors, reflecting analysts perspectives and market expectations.
Hover over the category for more information
Earnings
Earnings

Above analyst estimates
Rating
Rating

Upgraded on attractively valued
Momentum
Momentum

Has been gaining momentum
Activity
Activity
Future
Future

Earnings are forecast to grow

Outperform the market
![]()
INSM Analysts opinion is negative and it remained unchanged from the past 3 months
Analysts perspectives on the stock desirability, trend direction and growth potential
INSM Street Sentiment is extremely bullish and have positive views on the near-term outlook
INSM has Fair risk level based on volatility, sector strength, volume, investor confidence and outlook.
Click here to check what is your level of risk
Risks Indicators

Beta greater than 1.0

Average key support and resistance price levels
INSM Latest Analysis
Insmed Enters Oversold Territory (INSM). Legendary investor Warren Buffett advises to be fearful when others are greedy and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index or RSI which me
Today
Looking At Insmeds Recent Unusual Options Activity. Deep-pocketed investors have adopted a ish approach towards Insmed (NASDAQ:INSM) and it'.s something market players shouldn'.t ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown but such a substantial move in INSM usually suggests something big is about to happen.We gleaned this information from our observations today when Benzinga'.s optio
Today
Insmed Incorporated (INSM) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript.
Mon Jan 12, 2026
Insmed Incorporated (INSM) Presents at 44th Annual J.P. Morgan Healthcare Conference - Slideshow.
Mon Jan 12, 2026
INSM Stock Jumps on 2025 Preliminary Sales 2026 Goals Announced. Shares of Insmed rise after it tops FY25 sales forecasts led by strong Brinsupri uptake and outlines 2026 guidance and pipeline milestones.
Mon Jan 12, 2026
Insmed gains as preliminary 2025 revenue beats consensus.
Fri Jan 9, 2026
Nasdaq 100 Movers: MSTR INSM. In early trading on Friday shares of Insmed topped the list of the days best performing components of the Nasdaq 100 index trading up 4.9%. Year to date Insmed registers a 2.6% gain.And the worst performing Nasdaq 100 component thus far on the day is Strategy trading dow
Fri Jan 9, 2026
Insmed Maps Aggressive 2026 As Newly Approved Lung Disease Drug Gains Traction Pipeline Advances. INSM) on Friday outlined a commercial and clinical roadmap for 2026 highlighting strong momentum from its respiratory portfolio and a series of upcoming trial readouts and launches that could shape the company'.s .Speaking ahead of Insmed'.s presentation at the J.P. Morgan Healthcare Conference Insmed reported preliminary for full-year 2025 and approximately $144.6 million for the first ful
Fri Jan 9, 2026
Insmed Provides Business Update at 44th Annual J.P. Morgan Healthcare Conference. — BRINSUPRI® (brensocatib) Unaudited Total Revenues of Approximately $144.6 Million for First Full Quarter of Launch. Approximately $172.7 Million for Full-Year 2025— —ARIKAYCE® (amikacin liposome inhalation suspension) Exceeds the Upper End of Guidance Range for Full-Year 2025 with...
Fri Jan 9, 2026
Insmed stock rises after strong BRINSUPRI launch ARIKAYCE revenue beat.
Fri Jan 9, 2026
FIND US ON
Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts
In-depth stock analysis
Informed investment decisions
Stock market insights
Stock trading tips
INSM Stock trends
INSM Stock performance
INSM Stock analysis
INSM investment strategies
Disclaimer:
Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor.
The Readiness Indicators, Sentiment Indicators and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses.
Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.
Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").
This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.